

Mapping Dysfunctional Circuits in the Frontal Cortex Using Deep Brain Stimulation (Hollunder et al.): *Supplementary Tables*

Table of Contents

Supplementary Tables	p. 2
Table S1: Summary of demographic and clinical patient characteristics within each discovery cohort.	p. 2
Table S2: Patient-wise demographic and clinical characteristics of the dystonia discovery cohorts.	p. 4
Table S3: Patient-wise demographic and clinical characteristics of the Tourette's syndrome discovery cohorts.	p. 7
Table S4: Patient-wise demographic and clinical characteristics of the Parkinson's disease discovery cohorts.	p. 8
Table S5: Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder discovery cohorts.	p. 12
Table S6: Summary of demographic and clinical patient characteristics within each retrospective model validation cohort.	p. 13
Table S7: Patient-wise demographic and clinical characteristics of the Parkinson's disease validation cohorts.	p. 15
Table S8: Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder validation cohorts.	p. 17
Table S9: Peak voxel coordinates of subthalamic sweet spots and of disease-specific cortical sites of interconnection with sweet tracts.	p. 19
Table S10: Overlap between connected streamlines shared among disorders and disease-specific sweet streamlines.	p. 20
Table S11: Patient-wise demographic and clinical characteristics of patient cases for prospective model validations.	p. 20
References	p. 22

Table S1: Summary of demographic and clinical patient characteristics within each discovery cohort.

Disease cohort	DYT		PD		TS		OCD	
Demographic Information								
Cohort	San Francisco	Shanghai	Berlin	Würzburg	Pisa/Milan	Shanghai	London	Grenoble
Surgical DBS center	University of California San Francisco	Ruijin Hospital Shanghai	Charité - Universitäts- medizin Berlin	University Hospital Würzburg	Fondazione IRCCS Istituto Neurologico Carlo Besta Milan	Ruijin Hospital Shanghai	National Hospital for Neurology and Neurosurgery	University Hospital Grenoble
N (female)	12 (7)	Main*: 44 (23); Full: 58 (31)	51 (17)	43 (12)	4 (2)	10 (1)	6 (1)	13 (9)
Age at time of surgery (mean ± SD; range; in years)	56.08 ±16.06; 16-68	Main*: 39.43 ± 21.06, 7-74; Full: 41.90 ± 20.60, 7-74	59.98 ± 7.93.; 42-75	60.49 ± 8.23; 46-74	34.00 ± 8.83; 26-46	23.10 ± 9.39; 14-38	45.50 ± 10.52; 37-62	39.15 ± 8.23; 27-53
Disease duration at time of surgery (mean ± SD; range; in years)	9.50 ± 9.54; 2-32	Main*: 5.94 ± 7.01, 0.5-30; Full:5.15 ± 6.36, 0.25-30	10.38 ± 3.85; 5-21	12.53 ± 4.46; 5-23	24.25 ± 6.08; 19-33	14.8 ± 9.38; 3-30	24.17 ± 3.92; 20-30	18.92 ± 8.96; 5-39
Clinical Outcome								
Main clinical outcome assessment	BFMDRS ¹ (total score; range 0-120, with higher scores corresponding to higher symptom burden)		UPDRS-III ² (total score; range 0-199, with higher scores corresponding to higher symptom burden)		YGTSS ³ (global severity score; range 0-100, with higher scores corresponding to higher symptom burden)		Y-BOCS ⁴ (total score; range 0-40, with higher scores corresponding to higher symptom burden)	
Time of FU (in months)	6	Main*: mean = 19.09 ± 15.60 SD, range 6-84; Full: mean = 18.00 ± 15.56 SD, range 2-84	12	12	6	6	3 or 6 (post-amSTN phase) ⁺	12
Comparison basis for calculation of improvement values (baseline to DBS stimulation ON conditions)	Pre- to postoperative	Pre- to postoperative	Postoperative ON vs. OFF stimulation (ON dopaminergic medication)	Postoperative ON vs. OFF stimulation (ON dopaminergic medication)	Pre- to postoperative	Pre- to postoperative	Pre- to postoperative	Pre- to postoperative

Score at baseline (mean ± SD)	16.88 ± 9.30	Main*: 19.09 ± 17.68; Full: 16.40 ± 16.57	38.56 ± 12.92	49.84 ± 12.36	89.25 ± 5.25	69.70 ± 10.19	36.17 ± 1.83	33.54 ± 3.76
Score at time of FU under stimulation ON condition (mean ± SD)	6.88 ± 5.90	Main*: 6.02 ± 9.21; Full: 5.42 ± 8.33	20.12 ± 8.82	24.47 ± 10.62	34.25 ± 15.97	26.20 ± 17.92	19.83 ± 10.57	18.92 ± 10.74
Rel. improvement (mean ± SD; in %)	52.07 ± 41.71	Main*: 69.90 ± 23.46; Full: 65.24 ± 28.81	45.34 ± 23.03	49.46 ± 23.97	61.50 ± 17.81	62.31 ± 26.21	45.00 ± 29.33	43.59 ± 31.56
Abs. improvement (mean ± SD)	10.00 ± 10.83	Main*: 13.07 ± 14.72; Full: 10.97 ± 13.72	18.44 ± 11.31	25.37 ± 13.30	55.00 ± 17.00	43.50 ± 18.61	16.33 ± 10.67	14.62 ± 10.75

Imaging and DBS Specifications

Imaging modality (postoperatively)	MRI (N = 12)	Main*: CT (N = 44); Full: CT (N = 58)	MRI (N = 45), CT (N = 6)	CT (N = 43)	CT (N = 4)	CT (N = 10)	MRI (N = 6)	MRI (N = 10), CT (N = 3)
Electrode models	MDT 3389 (N = 12)	Main*: MDT 3387 (N = 17), PINS L302 (N = 17), SR 1210 (N = 10); Full: MDT 3387 (N = 22), PINS L302 (N = 26), SR 1210 (N = 10)	MDT 3389 (N = 51)	MDT 3389 (N = 44)	MDT 3389 (N = 4)	MDT 3387 (N = 2), SR 1210 (N = 7), PINS L302 (N = 1)	MDT 3389 (N = 6)	MDT 3389 (N = 14)
Related citation	Ostrem et al., 2011 ⁵ ; 2016 ⁶	Lin et al., 2019 ⁷ ; He, 2021 ⁸	Horn et al., 2017 ⁹ ; 2019 ¹⁰	Horn et al., 2017 ⁹ ; 2019 ¹⁰	Vissani et al., 2019 ¹¹	Dai et al., 2022 ¹²	Tyagi et al., 2019 ¹³	Polosan et al. 2019 ¹⁴

Notes: *The full sample of dystonia (DYT) patients from the Shanghai center (N = 58) is based on more liberal inclusion criteria compared to the sample reported on within the main manuscript (N = 44). More conservative exclusion criteria (baseline scores on the Burke-Fahn-Marsden Dystonia Rating Scale [BFMDRS] ≥ 5 and times of follow-up for postoperative assessments ≥ 6 months) were chosen for main analyses to ensure sufficiently stabilized and comparable deep brain stimulation (DBS) effects across cohorts. Results based on the full sample are reported in the supplements. *OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure amSTN” for the first three months or from months four to six postoperatively (and “pure VC/VS” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. AmSTN stimulation was applied via a Medtronic (MDT) model of type 3389, while MDT 3387 leads were implanted for stimulation of the VC/VS target zone (considered only for model validations, see below). *Abbreviations:* CT, computed tomography; DBS, deep brain stimulation; FU, follow-up; MRI, magnetic resonance imaging; OCD, obsessive-compulsive disorder; PD, Parkinson's disease; SD, standard deviation; SR, SceneRay; TS, Tourette's syndrome; UPDRS-III, Unified Parkinson's Disease Rating Scale – Part III; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale; YGTSS, Yale Global Tic Severity Scale.

Table S2: Patient-wise demographic and clinical characteristics of the dystonia discovery cohorts.

SAN FRANCISCO (N = 12)										
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	BFMDRS Baseline (total)	BFMDRS at FU (total)	BFMDRS Percent Improvement at FU (%)	Time of FU (months)	Symptom Sites	Genetic Mutation	Postop. Imaging Modality
1	41-45	F	8	19	2	89	6	oromandibular, cervical	none	MRI
2	46-50	M	7	14	14	0	6	cervical	none	MRI
3	41-45	F	2	34	1	97	6	cervical, trunk	none	MRI
4	36-40	F	9	8	3	63	6	cervical	none	MRI
5	51-55	F	3	12	3	75	6	face, neck	none	MRI
6	46-50	F	4	7	4	43	6	neck	none	MRI
7	51-55	F	32	10	4	60	6	arms	DYT-1 mutation	MRI
8	16-20	M	6	11,5	3,5	70	6	arms, neck	DYT-1 mutation	MRI
9	66-70	M	3	22	12,5	43	6	cervical	none	MRI
10	66-70	F	10	17	5,5	68	6	mouth, neck, and left hand	none	MRI
11	16-20	M	4	35	10	71	6	right arm, neck	DYT-1 mutation	MRI
12	51-55	M	26	13	20	-54	6	neck, arms	none	MRI
SHANGHAI (N = 44 in the main analysis, N = 58 in the supplemental analysis)										
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	BFMDRS Baseline (total)	BFMDRS at Follow-Up (total)	Percent Improvement at Follow-Up (%)	FU Period (months)	Dystonia Classification	Genetic Mutation	Postop. Imaging Modality
1	61-65	F	3	18	4,5	75	12	segmental	none	CT
2	41-45	F	1,5	8	5,5	31	15	segmental	none	CT
3	26-30	F	2	10	1	90	11	multi-focal	none	CT
4	21-25	F	5,3	9	2	78	12	generalized	none	CT
5	56-60	M	1,5	9	1,5	83	12	segmental	none	CT
6	56-60	F	1,5	10	2	80	18	segmental	none	CT

7	61-65	F	1,5	19	7	63	18	multi-focal	none	CT
8	71-75	M	1	11	5	55	12	segmental	none	CT
9	66-70	M	10	6	0,5	92	12	focal	none	CT
10	6-10	M	2	26	6	77	9	generalized	DYT-1 mutation	CT
11	31-35	F	2	6	3	50	12	focal	none	CT
12	51-55	M	30	26	7	73	17	multi-focal	DYT-24 mutation	CT
13	6-10	M	2	34	36	-6	12	multi-focal	none	CT
14	51-55	M	1,2	8	2	75	84	focal	none	CT
15	36-40	F	1	16,5	5	70	10	segmental	none	CT
16	36-40	M	6	47,5	1	98	8	generalized	none	CT
17	66-70	M	10	19,5	11	44	11	segmental	none	CT
18	6-10	M	6	24	4	83	24	multi-focal	none	CT
19	16-20	M	1,5	16	1,5	91	12	generalized	none	CT
20	21-25	M	1	5	1,5	70	10	segmental	none	CT
21	66-70	F	8	8,5	4,5	47	48	segmental	none	CT
22	66-70	F	1	11	3	73	30	segmental	none	CT
23	26-30	M	3,5	19	5	74	6	generalized	none	CT
24	41-45	M	3	10,5	4	62	24	generalized	none	CT
25	46-50	F	8	10	0,5	95	24	segmental	none	CT
26	41-45	F	15	8	2	75	30	generalized	none	CT
27	21-25	F	12	30	1	97	15	multi-focal	none	CT
28	11-15	M	2	21	2	90	18	generalized	none	CT
29	31-35	M	28	24	3	88	72	generalized	none	CT
30	51-55	F	6	16,5	4	76	7	generalized	none	CT
31	56-60	F	1,5	6	3	50	30	focal	none	CT
32	66-70	F	9	5	2,5	50	11	segmental	none	CT
33	51-55	F	9	49	49	0	12	multi-focal	none	CT
34	21-25	F	21	20	13	35	24	segmental	none	CT
35	16-20	M	2	92	19,5	79	24	generalized	none	CT
36	71-75	M	6,5	32,5	17	48	12	segmental	none	CT

37	36-40	M	1,5	20	7,5	63	18	generalized	none	CT
38	6-10	M	1	74	11	85	10	generalized	none	CT
39	6-10	F	0,5	16	1	94	13	multi-focal	none	CT
40	16-20	M	1	9	1	89	12	multi-focal	none	CT
41	36-40	F	15	6	1	83	8	segmental	none	CT
42	11-15	F	2	8	1	88	9	segmental	none	CT
43	56-60	F	1	6,5	1,5	77	16	segmental	none	CT
44	21-25	F	14	9	1	89	36	multi-focal	none	CT

Patients in the following list are included only in the supplemental analysis.

45	66-70	F	2,5	3	1,5	50	12	segmental	none	CT
46	31-35	M	1,5	4	1	75	24	segmental	none	CT
47	11-15	M	1	26	14,5	44	3	segmental	none	CT
48	51-55	F	0,3	3,5	1,5	57	12	segmental	none	CT
49	51-55	F	1	6	2	67	2	focal	none	CT
50	66-70	F	8,5	3,5	3	14	7	segmental	none	CT
51	46-50	M	3,5	3,5	1	71	60	segmental	none	CT
52	31-35	M	3	28	3	89	4	generalized	none	CT
53	61-65	M	7	8	0,5	94	3	segmental	none	CT
54	61-65	F	4	4	1	75	12	segmental	none	CT
55	46-50	M	0,25	9	12	-33	2	segmental	none	CT
56	71-75	F	3	4,5	5	-11	24	focal	none	CT
57	26-30	F	0,5	4	3	25	24	generalized	none	CT
58	51-55	F	1	4	0,5	88	13	multi-focal	none	CT

Abbreviations: BFMDRS, Burke-Fahn-Marsden Dystonia Rating Scale; CT, computed tomography; F, female; FU, follow-up; M, male; MRI, magnetic resonance imaging; Nr., number; postop. postoperative.

Table S3: Patient-wise demographic and clinical characteristics of the Tourette's syndrome discovery cohorts.

PISA/MILAN (N = 4)									
Patient Nr.	Age at surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	YGTSS Baseline	YGTSS at 6 mo. After Surgery	Percent Reduction from Baseline at 6 mo. (%)	Type of Tics	Comorbidities	Postop. Imaging Modality
1	26-30	F	23	92	22	76	pure motor	no OCD or major depression	CT
2	26-30	M	19	89	20	78	pure motor	no OCD or major depression	CT
3	31-35	F	22	94	53	44	pure motor	no OCD or major depression	CT
4	46-50	M	33	82	42	49	pure motor	no OCD or major depression	CT
SHANGHAI (N = 10)									
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	YGTSS Baseline	YGTSS at 6 mo. After Surgery	Percent Reduction from Baseline at 6 mo. (%)	Motor Tics: Body Regions Involved	Comorbidities	Postop. Imaging Modality
1	16-20	M	11	75	24	68	neck, shoulders, legs, feet	none	CT
2	11-15	M	9	71	4	94	eyes, neck	none	CT
3	11-15	M	3	68	6	91	arms, trunk, legs	none	CT
4	36-40	M	30	71	61	14	nose, mouth, neck, arms, hands, legs	anxiety	CT
5	16-20	F	12	59	8	86	eyes, nose, mouth, neck, shoulders, arms, hands	OCD, depression	CT
6	36-40	M	27	69	33	52	eyes, mouth, neck, shoulders, arms, hands	none	CT
7	16-20	M	6	76	36	53	eyes, mouth, neck, hands, legs	none	CT
8	26-30	M	16	63	17	73	eyes, nose, shoulders, trunk	OCD	CT
9	26-30	M	25	91	35	62	neck, shoulders, arms, legs, feet	OCD	CT
10	11-15	M	9	54	38	30	eyes, mouth, neck	none	CT

Abbreviations: CT, computed tomography; F, female; M, male; mo., months; Nr., number; OCD, obsessive-compulsive disorder; postop., postoperative; YGTSS, Yale Global Tic Severity Scale.

Table S4: Patient-wise demographic and clinical characteristics of the Parkinson's disease discovery cohorts.

Pat. Nr.	Age at surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	PD Phenotype*	UPDRS-III	UPDRS-III	UPDRS-III	UPDRS-III	UPDRS-III	LEDD Baseline (OFF DBS)	LEDD at 12 mo. Postop. (ON DBS)	LEDD Reduction (%)	Percent Improvement Levodopa Response	Postop. Imaging Modality
					Total Preop. Baseline (OFF medication)	Total Preop. Baseline (ON Medication)	Total Postop. (STIM OFF at 12 Mo.)	Total Postop. (STIM ON at 12 mo.)	Total Percent Improvement ON vs OFF STIM at 12 mo. postop. (%)					
BERLIN (N = 51)														
1	71-75	F	8	1	20	10	29	30	-3	968	498	49	50	MRI
2	56-60	M	10	1	33	20	41	23	44	900	725	19	39	MRI
3	66-70	F	12	1	n/a	n/a	54	36	33	1000	400	60	31	MRI
4	61-65	M	11	1	33	11	45	30	33	855	640	25	67	MRI
5	66-70	M	6	1	31	18	37	19	49	1035	1115	-8	42	MRI
6	46-50	M	5	1	29	3	39	15	62	610	0	100	90	MRI
7	56-60	F	7	1	n/a	n/a	52	29	44	1150	100	91	72	MRI
8	71-75	F	18	1	n/a	n/a	13	11	15	1500	650	57	26	CT
9	66-70	M	12	1	n/a	n/a	40	20	50	1650	475	71	54	CT
10	61-65	M	11	1	n/a	n/a	44	26	41	900	600	33	46	MRI
11	66-70	M	9	1	27	9	36	22	39	1275	1305	-2	67	MRI
12	51-55	M	7	1	36	20	46	30	35	1620	1000	38	44	MRI
13	66-70	M	14	1	25	14	28	17	39	1640	1398	15	44	CT
14	66-70	F	n/a	1	n/a	n/a	27	29	-7	n/a	n/a	n/a	n/a	MRI
15	61-65	M	11	1	16	9	28	13	54	3065	400	87	44	MRI
16	66-70	M	10	1	32	17	29	19	34	1170	780	33	47	MRI
17	51-55	M	8	1	n/a	n/a	24	9	63	1000	267	73	85	MRI
18	56-60	M	7	1	n/a	n/a	32,5	8	75	600	50	92	79	CT
19	71-75	M	9	1	n/a	n/a	27	20	26	1300	700	46	43	MRI
20	71-75	F	5	1	n/a	n/a	24	25	-4	650	700	-8	44	MRI
21	51-55	M	16	1	36	16	33	6	82	700	375	46	56	MRI

22	51-55	M	9	1	42	13	47	10	79	2000	553	72	69	MRI
23	61-65	M	14	1	n/a	n/a	28	15	46	1450	900	38	76	MRI
24	61-65	F	7	1	n/a	n/a	53	19	64	2050	600	71	30	MRI
25	61-65	F	8	1	n/a	n/a	46	28	39	700	200	71	71	MRI
26	61-65	M	7	1	21	12	28	13	54	1125	890	21	43	MRI
27	51-55	M	14	1	n/a	n/a	53	23	57	600	0	100	44	MRI
28	56-60	F	16	1	n/a	n/a	26	13	50	900	300	67	65	MRI
29	51-55	M	16	2	48	18	53	17	68	2438	423	83	63	MRI
30	56-60	M	13	1	n/a	n/a	59	14	76	1150	75	93	50	MRI
31	51-55	F	6	1	43	10	42	35	17	930	n/a	n/a	77	MRI
32	56-60	M	9	1	n/a	n/a	65	21	68	950	700	26	50	MRI
33	56-60	M	10	1	n/a	n/a	24	19	21	800	800	0	n/a	MRI
34	56-60	F	10	1	n/a	n/a	42	13	69	700	200	71	64	MRI
35	66-70	M	21	1	29	8	57	36	37	850	300	65	72	MRI
36	41-45	M	5	1	n/a	n/a	47	17	64	500	0	100	62	MRI
37	46-50	F	12	1	n/a	n/a	36	14	61	683	150	78	n/a	MRI
38	46-50	F	8	1	n/a	n/a	29	18	38	1400	0	100	52	MRI
39	56-60	M	7	1	n/a	n/a	21	9	57	333	50	85	n/a	CT
40	51-55	M	14	2	42	n/a	44	11	75	875	200	77	n/a	MRI
41	66-70	M	15	1	28	11	25	7	72	1328	360	73	61	CT
42	61-65	M	10	1	34	14	33	11	67	1100	720	35	59	MRI
43	66-70	M	17	2	60	21	71	40	44	1453	n/a	n/a	65	MRI
44	51-55	F	9	1	n/a	n/a	67	39	42	1200	375	69	n/a	MRI
45	41-45	F	12	2	n/a	n/a	40	27	33	1025	500	51	53	MRI
46	61-65	M	16	1	n/a	n/a	39	30	23	500	650	-30	31	CT
47	51-55	M	11	1	n/a	n/a	32	10	69	400	0	100	32	MRI
48	61-65	F	10	1	37	12	35	26	26	945	688	27	68	MRI
49	71-75	M	6	2	18	16	33	21	36	400	800	-100	11	MRI
50	51-55	F	5	1	n/a	n/a	45	13	71	750	50	93	25	MRI

51	51-55	M	6	3	13	7	18	20	-11	515	600	-17	46	MRI
WÜRZBURG (N = 43)														
1	51-55	M	13	1	78	46	78	36	54	1280	380	70	41	CT
2	56-60	M	13	1	53	25	53	28	47	1700	0	100	53	CT
3	56-60	M	20	1	43	12	43	15	65	2400	300	88	72	CT
4	66-70	M	16	1	49	18	49	30	39	1333	300	77	63	CT
5	46-50	F	21	1	36	3	36	33	8	1650	200	88	92	CT
6	56-60	F	15	1	43	13	43	25	42	1000	450	55	70	CT
7	61-65	M	15	1	43	8	43	23	47	1400	700	50	81	CT
8	66-70	M	16	1	55	21	55	40	27	2000	1050	48	62	CT
9	51-55	M	6	1	56	30	56	38	32	1275	850	33	46	CT
10	61-65	F	9	1	56	15	56	40	29	1800	700	61	73	CT
11	46-50	F	10	1	73	39	73	22	70	290	0	100	47	CT
12	66-70	M	13	1	71	36	71	40	44	1600	800	50	49	CT
13	66-70	F	12	1	47	14	47	14	70	1100	200	82	70	CT
14	61-65	F	12	1	31	10	31	36	-16	1450	950	34	68	CT
15	56-60	F	15	1	50	15	50	26	48	650	350	46	70	CT
16	71-75	F	17	1	59	15	59	14	76	1400	500	64	75	CT
17	46-50	M	23	1	52	29	52	12	77	1100	100	91	44	CT
18	56-60	M	6	1	43	10	43	13	70	2350	950	60	77	CT
19	66-70	F	14	1	60	19	60	17	72	500	300	40	68	CT
20	61-65	M	9	1	87	18	67	27	60	2000	950	53	79	CT
21	61-65	M	10	1	29	14	29	32	-10	1350	900	33	52	CT
22	51-55	F	6	1	47	18	47	20	57	2850	250	91	62	CT
23	56-60	M	18	1	40	10	40	31	23	1700	900	47	75	CT
24	66-70	M	14	1	51	38	51	23	55	1100	450	59	25	CT
25	51-55	M	5	1	26	3	26	5	81	650	400	38	88	CT
26	46-50	M	11	1	46	11	46	17	63	1100	200	82	76	CT

27	56-60	M	11	1	43	24	43	22	49	1000	150	85	44	CT
28	51-55	M	19	1	50	11	50	15	70	1800	600	67	78	CT
29	51-55	M	10	1	69	14	69	25	64	2600	550	79	80	CT
30	51-55	F	11	1	55	4	55	14	75	1320	980	26	93	CT
31	71-75	M	18	1	57	16	57	29	49	2020	688	66	72	CT
32	46-50	M	21	1	64	41	64	48	25	2320	813	65	36	CT
33	71-75	M	13	1	44	16	44	45	-2	1680	1640	2	64	CT
34	66-70	F	6	1	64	31	64	23	64	1033	460	55	52	CT
35	71-75	M	9	1	38	35	38	7	82	270	0	100	8	CT
36	61-65	M	11	3	38	22	38	19	50	988	105	89	42	CT
37	66-70	M	11	1	40	18	40	24	40	2040	1880	8	55	CT
38	46-50	M	13	1	44	23	44	24	45	1300	800	38	48	CT
39	46-50	M	9	1	37	22	37	22	41	1000	413	59	41	CT
40	61-65	M	10	1	67	18	67	39	42	2395	832	65	73	CT
41	61-65	M	9	1	52	23	52	19	63	916	733	20	56	CT
42	66-70	M	7	1	46	26	46	7	85	1020	443	57	43	CT
43	66-70	M	12	1	31	2	31	13	58	1068	0	100	94	CT

Notes: *Classification into Parkinson's disease (PD) phenotypes according to Schiess et al (2000) ¹⁵: 1= axial-rigid type. 2 = Mixed type, 3 = tremor dominant type. Abbreviations: CT, computed tomography; F, female; LEDD, levodopa equivalent daily dosage; M, male; Mo., months; MRI, magnetic resonance imaging; Nr., number; postop., postoperative; preop., preoperative; STIM, stimulation; UPDRS-III, Unified Parkinson's Disease Rating Scale – Part III.

Table S5: Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder discovery cohorts.

GRENOBLE (N = 13)									
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS at 12 Mo. after Surgery	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	31-35	M	13	32	26	19	checking, repeating	none	MRI
2	36-40	M	17	32	28	13	washing, ordering	anankastic personality	MRI
3	36-40	F	18	25	12	52	washing	none	MRI
4	26-30	F	24	34	30	12	checking	skin picking, hypothyroidia	MRI
5	51-55	F	25	40	16	60	washing	none	MRI
6	41-45	M	26	33	32	3	checking, hoarding	social phobia	MRI
7	51-55	F	22	33	2	94	checking	depression, Minkowski-Chauffard syndrome	MRI
8	36-40	F	11	36	6	83	washing	none	MRI
9	26-30	M	10	38	22	42	checking, washing	hypersomnia	CT
10	46-50	F	39	35	25	29	checking	None	CT
11	36-40	F	15	36	30	17	washing	history of eating disorder, history of one seizure, alcoholism, pruritus	MRI
12	36-40	F	5	32	3	91	checking	none	MRI
13	31-35	F	21	30	14	53	checking	dermatillomania	CT
LONDON (N = 6)									
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS after “amSTN only” Phase*	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	36-40	F	22	38	32* at 6 mo.	16	washing, repeating	none	MRI
2	36-40	M	22	34	26 at 6 mo.	23	ordering, checking, repeating	body dysmorphic disorder	MRI
3	61-65	M	30	37	17 at 6 mo.	55	washing, checking, repeating	none	MRI
4	36-40	M	20	38	20 at 3 mo.	47	washing, checking, ordering	recurrent depression	MRI
5	51-55	M	23	34	23 at 3 mo.	32	hoarding	recurrent depression	MRI
6	41-45	M	28	36	1 at 3 mo.	97	checking	generalized anxiety disorder, depression	MRI

Notes: *OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure amSTN” for the first three months or from months four to six postoperatively (and “pure VC/VS” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. AmSTN stimulation was applied via a Medtronic (MDT) model of type 3389, while MDT 3387 leads were implanted for stimulation of the VC/VS target zone (considered only for model validations, see below). *Abbreviations:* amSTN, anteromedial subthalamic nucleus; CT, computed tomography; F, female; M, male; mo., months; MRI, magnetic resonance imaging; Nr., number; OCD, obsessive-compulsive disorder; postop., postoperative; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

Table S6. Summary of demographic and clinical patient characteristics within each retrospective model validation cohort.

Disease cohort	PD	OCD		
Demographic Information				
Cohort	Würzburg	Boston	Cologne	London
Surgical DBS center	University Hospital Würzburg	Massachusetts General Hospital	University Hospital Cologne	National Hospital for Neurology and Neurosurgery
N (female)	32 (10)	7 (4)	22 (13)	6 (1)
Age at time of surgery (mean ± SD; range; in years)	58.00 ± 7.73; 46-79	38.86 ± 16.80; 21-64	42.20 ± 13.38; 21-64	45.50 ± 10.52; 37-62
Disease duration at time of surgery (mean ± SD; range; in years)	10.06 ± 4.21; 3-20	25.14 ± 14.21; 10-44	25.27 ± 12.29; 6-49	24.17 ± 3.92; 20-30
Clinical Outcome				
Surgical target	STN	VC/VS	VC/VS	VC/VS
Main clinical outcome assessment	UPDRS-III ² (total score; range 0-199, with higher scores corresponding to higher symptom burden)	Y-BOCS ⁴ (total score; range 0-40, with higher scores corresponding to higher symptom burden)	Y-BOCS ⁴ (total score; range 0-40, with higher scores corresponding to higher symptom burden)	Y-BOCS ⁴ (total score; range 0-40, with higher scores corresponding to higher symptom burden)
Time of FU (in months)	mean: 11.5 ± 3.08 SD; range: 6-22	18	12	3 or 6 (post-VC/VS phase)*

Comparison basis for calculation of improvement values (baseline to DBS stimulation ON conditions)	Postoperative ON vs. OFF stimulation (ON dopaminergic medication)	Pre- to postoperative	Pre- to postoperative	Pre- to postoperative
Score at baseline (mean ± SD)	45.84 ± 10.93	33.57 ± 2.37	31.12 ± 4.30	36.17 ± 1.83
Score at time of FU under stimulation ON condition (mean ± SD)	24.16 ± 10.65	20.29 ± 10.40	20.70 ± 7.70	17.00 ± 8.74
Rel. improvement (mean ± SD; in %)	46.90 ± 21.11	40.13 ± 29.84	31.00 ± 20.5	52.60 ± 25.51
Abs. improvement (mean ± SD)	21.69 ± 10.96	13.29 ± 9.55	9.60 ± 6.50	19.17 ± 9.39
Imaging and DBS Specifications				
Imaging modality (postop.)	CT (N = 32)	CT (N = 7)	CT (N = 22)	MRI (N = 6)
Electrode models	BSV (N = 23) or BSV Directed (N = 9)	MDT 3387 (N = 7)	MDT 3387 (N = 3) or MDT 3389 (N = 19)	MDT 3387 (N = 6)
Related citations	Butenko et al., 2022 ¹⁶	McLaughlin et al., 2021 ¹⁷	Baldermann et al., 2019 ¹⁸ ; Li et al., 2020 ¹⁹ , 2021 ²⁰	Tyagi et al., 2019 ¹³

Notes: *OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure VC/VS” for the first three months or from months four to six postoperatively (and “pure amSTN” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. VC/VS stimulation was applied via a Medtronic (MDT) model of type 3387 (considered only for model validations), while MDT 3389 leads were implanted for stimulation of the amSTN target zone (considered only for the model set-up step). *Abbreviations:* Abs., absolute; BSV, Boston Scientific Vercise; CT, computed tomography; DBS, deep brain stimulation; FU, follow-up; MRI, magnetic resonance imaging; OCD, obsessive-compulsive disorder; PD, Parkinson’s disease; postop., postoperative; Rel., relative; SD, standard deviation; UPDRS-III, Unified Parkinson’s Disease Rating Scale – Part III; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

Table S7: Patient-wise demographic and clinical characteristics of the Parkinson's disease validation cohorts.

Pat. Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	UPDRS-III Total Preop. Baseline (OFF Medication)	UPDRS-III Total Preop. Baseline (ON Medication)	UPDRS-III Total Postop. (STIM ON at FU)	UPDRS-III Total Percent Improvement ON vs. OFF STIM at FU (%)	LEDD Baseline (OFF DBS)	Time of FU (months)	Postop. Imaging Modality
WÜRZBURG (N = 32)										
1	56-60	M	12	48	9	17	65	81	12	CT
2	56-50	F	9	62	27	38	39	56	12	CT
3	61-65	F	12	42	22	17	60	48	12	CT
4	46-50	M	18	52	34	34	35	35	10	CT
5	56-60	M	7	56	9	17	70	84	16	CT
6	56-60	M	12	49	20	24	51	59	12	CT
7	71-75	M	10	40	20	28	30	50	22	CT
8	56-60	F	11	44	10	8	82	77	12	CT
9	61-65	M	5	45	12	27	40	73	12	CT
10	51-55	F	3	61	34	39	36	44	12	CT
11	61-65	M	11	45	11	32	29	76	12	CT
12	51-55	F	6	31	10	16	48	68	12	CT
13	46-50	M	12	47	20	36	23	57	12	CT
14	46-50	M	7	44	20	14	68	55	13	CT
15	46-50	M	7	38	13	9	76	66	12	CT
16	66-70	M	8	45	5	48	-7	89	13	CT
17	51-55	M	9	50	13	26	48	74	12	CT
18	46-50	M	9	44	17	21	52	61	12	CT
19	61-65	M	6	39	18	35	10	54	12	CT
20	51-55	M	8	16	8	10	38	50	12	CT
21	56-60	M	10	52	38	24	54	27	12	CT
22	56-60	F	18	41	14	22	46	66	12	CT

23	66-70	F	17	45	18	7	84	60	12	CT
24	61-65	M	9	44	23	19	57	48	12	CT
25	76-80	M	5	42	26	25	40	38	12	CT
26	61-65	F	16	39	14	28	28	64	12	CT
27	56-60	M	8	42	33	39	7	21	12	CT
28	46-50	F	12	40	19	20	50	53	6	CT
29	56-60	M	20	85	42	42	51	51	6	CT
30	56-60	M	13	51	25	20	61	51	6	CT
31	51-55	F	6	41	7	14	66	83	6	CT
32	61-65	M	6	47	22	17	64	53	6	CT

Abbreviations: CT, computed tomography; F, female; FU, follow-up; LEDD, levodopa equivalent daily dosage; M, male; MRI, magnetic resonance imaging; Nr., number; postop., postoperative; preop., preoperative; STIM, stimulation; UPDRS-III, Unified Parkinson's Disease Rating Scale – Part III.

Table S8: Patient-wise demographic and clinical characteristics of the obsessive-compulsive disorder validation cohorts.

BOSTON (N = 7)									
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS at 18 Mo. after Surgery	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	56-60	M	41	32	0	100	doubt, checking	n/a	CT
2	21-25	F	13	35	16	54	doubt, checking	n/a	CT
3	61-65	F	44	32	21	34	contamination, cleaning	n/a	CT
4	21-25	M	10	33	29	12	doubt, checking	n/a	CT
5	26-30	F	11	34	22	35	doubt, checking	n/a	CT
6	41-45	F	27	31	22	29	contamination, cleaning	n/a	CT
7	36-40	M	30	38	32	16	contamination, cleaning	n/a	CT
COLOGNE (N = 22)									
Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS at 12 Mo. after Surgery	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	36-40	M	24	30	8	73	magical thinking, incompleteness, responsibility	recurrent major depressive disorder (moderate)	CT
2	31-35	M	15	34	34	0	washing, contamination	none	CT
3	36-40	M	27	33	24	27	washing, contamination, symmetry, catastrophic fears	none	CT
4	51-55	M	6	34	12	65	washing, controlling, contamination fears, aggressive thought	none	CT
5	26-30	M	22	27	14	48	contamination, aggressive impulses, symmetry	none	CT
6	21-25	M	18	25	20	20	repetition, keeping order, mental exactness, checking	none	CT
7	21-25	F	15	35	23	34	bodydysmorphobia, checking, magical thinking	hypochondriasis	CT
8	46-50	M	24	32	22	31	somatic obsessions, contamination fears	none	CT
9	31-35	M	19	37	34	8	cleanliness, washing, contamination fears, disgust	none	CT

10	46-50	F	19	28	13	54	checking, aggressive fears, responsibility	none	CT
11	56-60	F	49	36	22	39	aggressive thoughts/impulses, mental urges	recurrent major depressive disorder (severe without psychotic features)	CT
12	26-30	F	6	26	16	38	aggressive impulses, checking, doubting	none	CT
13	61-65	F	20	25	18	28	catastrophic fears, responsibility	anxiety disorder (not otherwise specified); recurrent major depressive disorder (moderate)	CT
14	56-60	M	35	35	25	29	catastrophic fears, responsibility	recurrent major depressive disorder (moderate)	CT
15	26-30	M	18	33	22	33	aggressive impulses, responsibility	recurrent major depressive disorder (severe without psychotic features)	CT
16	56-60	M	44	25	20	20	aggressive impulses, responsibility	recurrent major depressive disorder (severe without psychotic features)	CT
17	36-40	F	29	30	28	7	magical thinking, incompleteness, mental urges	recurrent major depressive disorder (moderate)	CT
18	41-45	F	34	26	21	19	aggressive impulses, responsibility, checking	none	CT
19	41-45	F	39	37	27	27	mental rituals/urges, magical thinking	none	CT
20	51-55	M	42	34	29	15	contamination, cleanliness	none	CT
21	36-40	M	11	36	36	0	responsibility, catastrophic fears, checking	recurrent major depressive disorder (moderate)	CT
22	56-60	F	40	32	11	66	somatic obsessions, sexual obsessions	sedative, hypnotic, or anxiolytic dependence	CT

LONDON (N = 6)

Patient Nr.	Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	Y-BOCS Baseline	Y-BOCS after "VC/VS only" Phase ⁺	Percent Reduction from Baseline (%)	OCD Subtype	Comorbidities	Postop. Imaging Modality
1	36-40	F	22	38		16	washing, repeating	none	MRI
2	36-40	M	22	34		23	ordering, checking, repeating	body dysmorphic disorder	MRI

3	61-65	M	30	37	55	washing, checking, repeating	none	MRI
4	36-40	M	20	38	47	washing, checking, ordering	recurrent depression	MRI
5	51-55	M	23	34	32	hoarding	recurrent depression	MRI
6	41-45	M	28	36	97	checking	generalized anxiety disorder, depression	MRI

Notes: *OCD patients from London were bilaterally implanted with DBS electrodes to two different target sites (four electrodes per patient) – the anteromedial subthalamic nucleus (amSTN) and the ventral capsule/ventral striatum (VC/VS). Patients were randomly assigned to either receive “pure VC/VS” for the first three months or from months four to six postoperatively (and “pure amSTN” for the remainder of the first six months). Model set-up (based on the discovery cohort) was informed on stimulation parameters and corresponding clinical scores taken after the amSTN phase, while model validation was performed based on VC/VS-stimulation related data points. VC/VS stimulation was applied via a Medtronic (MDT) model of type 3387 (considered only for model validations), while MDT 3389 leads were implanted for stimulation of the amSTN target zone (considered only for the model set-up step). *Abbreviations:* CT, computed tomography; F, female; M, male; mo., months; MRI, magnetic resonance imaging; Nr., number; OCD, obsessive-compulsive disorder; postop., postoperative; VC/VS, ventral capsule/ventral striatum; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.

Table S9: Peak voxel coordinates of subthalamic sweet spots and of disease-specific cortical sites of interconnection with sweet tracts.

		DYT			TS			PD			OCD		
		(x	y	z)	(x	y	z)	(x	y	z)	(x	y	z)
Cortical sites of interconnection with sweet tracts (in mm)	Left	(-22.00	-20.00	72.00)	(-3.32	-29.65	-45.59)	(-14.00	2.00	70.00)	(-8.23	-10.29	-16.50)
	Right	(23.50	-18.75	72.00)	(10.00	-12.00	-16.50)	(10.00	2.00	70.00)	(7.88	-9.50	-16.50)
Subthalamic sweet spots (in mm)	Left	(-14.72	-14.38	-4.10)	(-12.96	-11.08	-6.30)	(-12.08	-13.94	-6.74)	(-8.78	-11.52	-9.60)
	Right	(14.54	-13.50	-4.30)	(13.00	-9.98	-6.08)	(11.90	-13.28	-6.74)	(8.38	-10.86	-9.38)

Abbreviations: DYT, dystonia; mm, millimeters; OCD, obsessive-compulsive disorder; PD, Parkinson’s disease; TS, Tourette’s syndrome.

Table S10: Overlap between connected streamlines shared among disorders and disease-specific sweet streamlines.

	DYT	PD	TS	OCD
Overlap (%)	4.41	2.21	1.75	5.42
Four-sample test for equality of proportions	p < 2.2e-16			
Pairwise test for equality of proportions				
DYT				
PD	p < 2.2e-16			
TS	p < 2.2e-16	p < 2.84e-14		
OCD	p < 1.35e-11	p < 2.2e-16	p < 2.2e-16	

Abbreviations: DT, dystonia; mm, millimeters; OD, obsessive-compulsive disorder; PD, Parkinson's disease; TS, Tourette's syndrome.

Table S11: Patient-wise demographic and clinical characteristics of patient cases for prospective model validations.

PD												
Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	PD Phenotype	UPDRS-III Total Postop. (STIM OFF, Med. OFF at 3 Mo.)	UPDRS-III Total Postop. (STIM ON under Clinical Settings, Med. OFF at 3 Mo.)	UPDRS-III Total Postop. (STIM ON under Model-Based Settings, Med. OFF at 3 Mo.)	UPDRS-III Total Improvement ON vs OFF STIM at 3 Mo. postop. (under Clinical Settings, Med. OFF , %)	UPDRS-III Total Improvement ON vs OFF STIM at 3 Mo. postop. (under Model-Based Settings, Med. OFF , %)	Electrode Model	Clinical Settings	Model-Based Settings	Postop. Imaging Modality
PD patient implanted to the STN at Würzburg University Hospital (Würzburg, Germany)												
66-70	M	9	Akinetik-rigid	35	14	10	60	71	BSV Directed	Left hemisphere: C+, 1- (60%), 2- (40%) / 2.4 mA / 60 µs / 130 Hz; Right hemisphere.: C+, 1- (20%), 2- (20%), 3- (3%), 4- (57%) / 2.6 mA / 60 µs / 130 Hz	Left hemisphere: C+, 4- (70%), 7- (30%) / 3 mA / 60 µs / 130 Hz; Right hemisphere: C+, 7- (30%), 8- (70%) / 3 mA / 60 µs / 130 Hz	CT

OCD														
Age at Surgery (within range, in years)	Sex	Disease Duration at Surgery (years)	OCD Phenotype	Comorbidities	Previous treatments	Y-BOCS Total Preop.	Y-BOCS Total	Y-BOCS Total	Y-BOCS Total	Y-BOCS Total	Electrode Model	Clinical Settings	Model-Based Settings	Postop. Imaging Modality
							Postop. (STIM ON under Clinical Settings at 1 Mo. Postop.)	Postop. (STIM ON under Model-Based Settings at 1 Mo. Postop.)	Improvement Preop. vs. STIM ON at 1 Mo. Postop. (under Clinical Settings, %)	Improvement Preop. Vs. STIM ON at 1 Mo. Postop. (under Model-Based Settings, %)				
OCD patient implanted to the VC/VS region at Massachusetts General Hospital (Boston, USA)														
21-25	F	13	obsessions about food and water intake, compulsions involving ingestion events; skin picking	major depressive disorder	11 different medication trials (including multiple SSRIs, clomipramine, and ketamine), intensive ERP, ECT	35	29	22	17	37	MDT 3387	Left hemisphere: C+, 1- , 2- / 3 mA / 140 μs / 130 Hz; Right hemisphere: C+, 9- / 2.4 mA / 140 μs / 130 Hz;	Left hemisphere: C+, 2- / 4.2 mA / 80 μs / 130 Hz; Right hemisphere: C+, 10- / 3.4 mA / 80 μs / 130 Hz;	CT
OCD patient implanted to the STN at Clínica de Dor e Funcional (São Paulo, Brazil)														
31-35	M	14	compulsion of noting words unknown to the patient and transcribing their meaning from dictionaries; death-related intrusions leading to compulsive religious rituals	apathy, major depressive disorder	48 sessions of ECT, CBT, biofeedback, mindfulness training, 3 different protocols of TMS with over 50 sessions	26	-	6	-	77	BSV	-	Left hemisphere: C+, 1- (100%) / 3 V / 90 μs / 130 Hz; Right hemisphere: C+, 9- (100%) / 3 V / 90 μs / 130 Hz;	CT
Abbreviations: BSV, Boston Scientific Vercise; CBT, cognitive behavioral therapy; CT, computed tomography; ECT, electroconvulsive therapy; ERP, exposure and response prevention therapy; F, female; Hz, Hertz; M, male; mA, milliampere; Mo., months; MDT, Medtronic; postop., postoperative; preop., preoperative; postop., postoperative; SSRI, selective serotonin inhibitor; STIM, stimulation; STN, subthalamic nucleus; TMS, transcranial magnetic stimulation; UPDRS III, Unified Parkinson's Disease Rating Scale – Part III; VC/VS, ventral capsule/ventral striatum; V, volt; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.														

References

1. Burke, R. E. *et al.* Validity and reliability of a rating scale for the primary torsion dystonias. *Neurology* **35**, 73–77 (1985).
2. Goetz, C. G. *et al.* Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan. *Mov. Disord.* **22**, 41–47 (2007).
3. Leckman, J. F. *et al.* The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. *J. Am. Acad. Child Adolesc. Psychiatry* **28**, 566–573 (1989).
4. Goodman, W. K. *et al.* The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. *Arch. Gen. Psychiatry* **46**, 1006–1011 (1989).
5. Ostrem, J. L. *et al.* Subthalamic nucleus deep brain stimulation in primary cervical dystonia. *Neurology* **76**, 870–878 (2011).
6. Ostrem, J. L. *et al.* Subthalamic nucleus deep brain stimulation in isolated dystonia: A 3-year follow-up study. *Neurology* **88**, 25–35 (2016).
7. Lin, S. *et al.* Deep brain stimulation of the globus pallidus internus versus the subthalamic nucleus in isolated dystonia. *J. Neurosurg.* **132**, 721–732 (2019).
8. He, W. *et al.* Weight change after subthalamic nucleus deep brain stimulation in patients with isolated dystonia. *Front. Neurol.* **12**, 1–8 (2021).
9. Horn, A. *et al.* Connectivity predicts deep brain stimulation outcome in Parkinson's disease. *Ann. Neurol.* **82**, 67–78 (2017).
10. Horn, A. *et al.* Deep brain stimulation induced normalization of the human functional connectome in Parkinson's disease. *Brain* **142**, 3129–3143 (2019).
11. Vissani, M. *et al.* Spatio-temporal structure of single neuron subthalamic activity identifies DBS target for anesthetized Tourette Syndrome patients. *J. Neural Eng.* **16**, 066011 (2019).
12. Dai, L. *et al.* Subthalamic deep brain stimulation for refractory Gilles de la Tourette's syndrome: Clinical outcome and functional connectivity. *J. Neurol.* **269**, 6116–6126 (2022).
13. Tyagi, H. *et al.* A randomized trial directly comparing ventral capsule and anteromedial subthalamic nucleus stimulation in obsessive-compulsive disorder: Clinical and imaging evidence for dissociable effects. *Biol. Psychiatry* **85**, 726–734 (2019).
14. Polosan, M. *et al.* Affective modulation of the associative-limbic subthalamic nucleus: deep brain stimulation in obsessive-compulsive disorder. *Transl. Psychiatry* **9**, (2019).
15. Schiess, M. C., Zheng, H., Soukup, V. M., Bonnen, J. G. & Nauta, H. J. W. Parkinson's disease subtypes: Clinical classification and ventricular cerebrospinal fluid analysis. *Park. Relat. Disord.* **6**, 69–76 (2000).
16. Butenko, K. *et al.* Linking profiles of pathway activation with clinical motor improvements – A retrospective computational study. *NeuroImage Clin.* **36**,

103185 (2022).

17. McLaughlin, N. C. R. *et al.* Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design. *Contemp. Clin. Trials Commun.* **22**, 100785 (2021).
18. Baldermann, J. C. *et al.* Connectivity profile predictive of effective deep brain stimulation in obsessive-compulsive disorder. *Biol. Psychiatry* **85**, 735–743 (2019).
19. Li, N. *et al.* A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder. *Nat. Commun.* **11**, 3364 (2020).
20. Li, N. *et al.* A unified functional network target for deep brain stimulation in obsessive-compulsive disorder. *Biol. Psychiatry* **90**, 701–713 (2021).